HALO - Halozyme Therapeutics, Inc.
| Previous Close | 18.24 |
| Open | 18.18 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 800 |
| Day's Range | 18.18 - 18.81 |
| 52 Week Range | 11.41 - 21.48 |
| Volume | 484,077 |
| Avg. Volume | 912,708 |
| Market Cap | 2.686B |
| Beta | 2.96 |
| PE Ratio (TTM) | 41.69 |
| EPS (TTM) | 0.45 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.91 |
- ACCESSWIRE•9 days ago
Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Major U.S. markets closed up on Monday, with the Dow Jones posting its 8th consecutive daily gain, as trade tensions between U.S. and China eased. The Dow Jones ...
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Halozyme Therapeutics Inc Earnings Call
- Associated Press•13 days ago
Halozyme Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- PR Newswire•13 days ago
Halozyme Reports First Quarter 2018 Results
-- Revenue of $30.9 Million Includes a 50 Percent Increase in Royalty Revenue on a Reported Basis -- -- Eight ENHANZE®-Partnered Products Expected in Clinical Studies in 2018, Two More than Forecasted ...
Markit•15 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•last monthSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•last month
Halozyme To Host First Quarter 2018 Financial Results Conference Call
SAN DIEGO , April 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Business Wire•2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
- PR Newswire•2 months ago
Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
SAN DIEGO, March 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the nomination of Jean-Pierre Bizzari, M.D. and James M. Daly as Class II directors for reelection at the Company's 2018 stockholder meeting. Following communication by Randal J. Kirk of his unavailability for further service due to growing commitments outside Halozyme, it has been agreed that Mr. Kirk will not be nominated for reelection to the board of directors. Mr. Kirk joined the board of directors nearly 11 years ago at a formative time for the company and remains Halozyme's largest shareholder.
- PR Newswire•2 months ago
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
SAN DIEGO , March 14, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical data from ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of HALO earnings conference call or presentation 20-Feb-18 9:30pm GMT
Q4 2017 Halozyme Therapeutics Inc Earnings Call
- PR Newswire•3 months ago
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the Cowen & Company ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
- GlobeNewswire•3 months ago
New Research: Key Drivers of Growth for Trinseo S.A, Camden Property Trust, Lions Gate Entertainment, Aramark, J.M. Smucker, and Halozyme Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trinseo ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Halozyme shares closed up roughly 4% on Wednesday after the company announced strong fourth quarter results earlier in the week. Shares of Loxo Oncology ...
- Associated Press•3 months ago
Halozyme Therapeutics tops Street 4Q forecasts
The San Diego-based company said it had profit of 85 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings ...
- PR Newswire•3 months ago
Halozyme Reports Fourth Quarter And Full-Year 2017 Results
-- Continued Momentum from ENHANZE® Technology with Q4 Royalty Revenue Increasing 24 Percent from Prior-Year Period to $17.7 million -- -- HALO-301 Study of Investigational New Drug PEGPH20 Remains on ...
- ACCESSWIRE•3 months ago
Halozyme Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 4:30 PM ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
- Zacks•3 months ago
Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock
Halozyme Therapeutics (HALO) needs investors to pay close attention to the stock based on moves in the options market lately.
- Simply Wall St.•3 months ago
Halozyme Therapeutics Inc (NASDAQ:HALO): Should The Recent Earnings Drop Worry You?
When Halozyme Therapeutics Inc (NASDAQ:HALO) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happeningRead More...
- GuruFocus.com•4 months ago
First Eagle Reduces Halozyme Therapeutics Stake
The firm has a sizable gain on cancer treatment company
Markit•4 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GuruFocus.com•4 months ago
First Eagle Fund of America 4th Quarter Commentary
Review of holdings and markets
- CNBC Videos•4 months ago
Cramer's lightning round: Shopify's doing well, but you s...
Jim Cramer flies through his take on callers' favorite stocks at lightning speed, including an e-commerce play.
